NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment last...
Sapient, a biomarker discovery organization providing bespoke services for multi-omics data generation and analysis, has announced the roll-out of its high...
Meningitis, characterized by inflammation of the protective membranes enveloping the brain and spinal cord, poses a grave medical emergency due to ...
The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...
The company's commitment to advancing human potential through science is evident in its transformative approach and a diverse portfolio of specialize...
Nikon Instruments Inc. (Nikon) is pleased to announce the establishment of the Nikon BioImaging Lab Lexington in Massachusetts, USA, where it will provide ...
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo&nbs...
Strategic collaboration to open a new chapter in the field of molecular diagnostics that aspires to 'a world free from all diseases and future pandemics'...
-DNAnexus, Inc., the provider of the Precision Health Data Cloud, and TMA Precision Health, a global health platform for rare diseases, announced a collabo...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
Glass vials are regularly used for pharmaceutical packaging, though there is a growing market need for primary packaging that is suited to more sensitive, ...
First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free surv...
In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide ...
The newly granted patent, EP3927337, which will have an effective date of February 14, 2024, and an expiry date of no earlier than 2040, is expected to cov...
© 2025 Biopharma Boardroom. All Rights Reserved.
